Research graph
References from Mental Health and Substance Use Disorder Expenditures in the US. Local targets link to admitted publications; unresolved targets remain external evidence.
Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication.
10.1001/archpsyc.62.6.603 · 2005 · External reference
Probability and predictors of first treatment contact for anxiety disorders in the United States: analysis of data from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).
10.4088/jcp.13m08361 · 2013 · External reference
Probability and predictors of treatment-seeking for substance use disorders in the U.S.
10.1016/j.drugalcdep.2015.01.031 · 2015 · External reference
Barriers to mental health treatment: results from the National Comorbidity Survey Replication.
10.1017/s0033291710002291 · 2011 · External reference
Opportunities and needs to advance prevention of substance use disorders.
10.1001/jamapediatrics.2025.0007 · 2025 · External reference
US national spending on mental health and substance use disorder treatment driven by case growth, 2000-21.
10.1377/hlthaff.2025.01351 · 2026 · External reference
The burden of diseases, injuries, and risk factors by state in the USA, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
10.1016/s0140-6736(24)01446-6 · 2024 · External reference
Measuring disparities across the distribution of mental health care expenditures.
2013 · External reference
Using machine-learning algorithms to improve imputation in the Medical Expenditure Panel Survey.
10.1111/1475-6773.14115 · 2023 · External reference
Trends in psychological distress and outpatient mental health care of adults during the COVID-19 era.
10.7326/m23-2824 · 2024 · External reference
A note on robust variance estimation for cluster-correlated data.
10.1111/j.0006-341x.2000.00645.x · 2000 · External reference
Tracking US health care spending by health condition and county.
10.1001/jama.2024.26790 · 2025 · External reference
Differential reimbursement of psychiatric services by psychiatrists and other medical providers.
10.1176/appi.ps.201700271 · 2018 · External reference
Research on substance use disorders during the COVID-19 pandemic.
10.1016/j.jsat.2021.108385 · 2021 · External reference
Expanding current approaches to solve the opioid crisis.
10.1001/jamapsychiatry.2021.3136 · 2022 · External reference
Addiction consultation services for opioid use disorder treatment initiation and engagement: a randomized clinical trial.
10.1001/jamainternmed.2024.3422 · 2024 · External reference
Management of depression in adults: a review.
10.1001/jama.2024.5756 · 2024 · External reference
Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021.
10.1001/jamanetworkopen.2023.27488 · 2023 · External reference
Regulators, payors, and the impact of measurement-based care on value-based care in psychiatry.
10.1016/j.chc.2020.05.001 · 2020 · External reference
Effect of first episode axis I disorders on quality of life.
10.1097/nmd.0000000000000117 · 2014 · External reference
Quality of life following remission of mental disorders: findings from the National Epidemiologic Survey on Alcohol and Related Conditions.
10.4088/jcp.12m08269 · 2013 · External reference
Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation.
10.1001/jama.284.13.1689 · 2000 · External reference
Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey.
10.1001/archpsyc.1994.03950010008002 · 1994 · External reference
Sociodemographic and psychopathologic predictors of first incidence of DSM-IV substance use, mood and anxiety disorders: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions.
10.1038/mp.2008.41 · 2009 · External reference
Mapping common psychiatric disorders: structure and predictive validity in the National Epidemiologic Survey on Alcohol and Related Conditions.
10.1001/jamapsychiatry.2013.281 · 2013 · External reference
Examining heterotypic continuity of psychopathology: a prospective national study.
10.1017/s003329171700054x · 2017 · External reference
Probability and predictors of remission from life-time nicotine, alcohol, cannabis or cocaine dependence: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
10.1111/j.1360-0443.2010.03194.x · 2011 · External reference
Predictors of persistence of social anxiety disorder: a national study.
10.1016/j.jpsychires.2011.08.004 · 2011 · External reference
Persistence of chronic major depression: a national prospective study.
10.1016/j.jad.2013.06.013 · 2013 · External reference
Testing the drug substitution switching-addictions hypothesis: a prospective study in a nationally representative sample.
10.1001/jamapsychiatry.2014.1206 · 2014 · External reference
A comprehensive model of predictors of persistence and recurrence in adults with major depression: results from a national 3-year prospective study.
10.1016/j.jpsychires.2017.07.022 · 2017 · External reference
A comprehensive model of predictors of recurrence or persistence in individuals with panic disorder: results from a national 3-year prospective study.
10.4088/jcp.20m13778 · 2022 · External reference
Trends in serious psychological distress and outpatient mental health care of US adults.
10.1001/jamapsychiatry.2018.3550 · 2019 · External reference
Implementing measurement-based care in behavioral health: a review.
10.1001/jamapsychiatry.2018.3329 · 2019 · External reference
A population-level approach to the treatment of psychiatric disorders.
10.1038/s41380-026-03738-6 · External reference
Prospects of GLP-1 therapies for addiction and mental health comorbidities—quo vadis?: a review.
10.1001/jamapsychiatry.2025.4308 · 2026 · External reference
GLP-1R agonist medications for addiction treatment.
10.1111/add.16626 · 2025 · External reference
The social determinants of mental health and disorder: evidence, prevention and recommendations.
10.1002/wps.21160 · 2024 · External reference
Toward a generalized developmental model of psychopathological liabilities and psychiatric disorders.
10.1017/s0033291721005468 · 2023 · External reference
From scientific discovery to covered treatments: understanding the payer perspective as a keystone to achieving high-value care.
10.1001/jama.2022.6469 · 2022 · External reference
Public insurance expansions and mental health care availability.
10.1111/1475-6773.13311 · 2020 · External reference
In the shadow of a giant: Medicare’s influence on private physician payments.
10.1086/689772 · 2017 · External reference
Trading spaces: Medicare’s regulatory spillovers on treatment setting for non-Medicare patients.
10.1016/j.jhealeco.2022.102624 · 2022 · External reference
Coding inequities in psychiatric care: a call to align DSM/ICD with chronic disease management.
10.1176/appi.ajp.20250629 · 2026 · External reference
Has corporatization met its match? the challenge of making money by keeping people healthy.
10.1056/nejmp2513434 · 2025 · External reference
Accuracy of Medicare expenditures in the Medical Expenditure Panel Survey.
10.5034/inquiryjrnl_46.01.92 · 2009 · External reference
Assessing the representativeness of Medical Expenditure Panel Survey inpatient utilization data for individuals with psychiatric and nonpsychiatric conditions.
10.1177/1077558715592745 · 2015 · External reference
Unresolved reference
2014 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2022 · External reference
Unresolved reference
2009 · External reference
Unresolved reference
2017 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
